Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCAINAMIDE HCL vs DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.
Dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; quinidine is a CYP2D6 inhibitor that increases dextromethorphan bioavailability.
Treatment of documented ventricular arrhythmias (e.g., sustained ventricular tachycardia) that are life-threatening,Off-label: Atrial fibrillation, atrial flutter, supraventricular tachycardia, Wolff-Parkinson-White syndrome
Pseudobulbar affect (PBA) - FDA approved
For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.
One capsule (dextromethorphan 20 mg/quinidine 10 mg) orally once daily, with a maximum dose of two capsules per day.
Terminal elimination half-life: 2.5-4.7 hours (3 hours typical) in normal renal function; prolonged to 11-20 hours in renal impairment; NAPA half-life 6-8 hours (prolonged in renal failure).
Dextromethorphan: 2-4 hours (extensive metabolizers); quinidine: 6-8 hours (inhibits CYP2D6, prolonging dextromethorphan half-life in poor metabolizers to >20 hours)
Hepatic via N-acetyltransferase (NAT2) to N-acetylprocainamide (NAPA); also undergoes hydrolysis to p-aminobenzoic acid.
Dextromethorphan is primarily metabolized by CYP2D6 to dextrorphan; quinidine is a potent CYP2D6 inhibitor at low doses.
Primarily renal (50-60% unchanged via glomerular filtration and tubular secretion) with 10-30% as N-acetylprocainamide (NAPA) metabolite; minor biliary/fecal (<5%).
Renal: quinidine 15-25% unchanged, dextromethorphan <1% unchanged; biliary/fecal: quinidine metabolites ~5%, dextromethorphan metabolites ~60-80% as dextrorphan conjugates
15-25% bound primarily to alpha-1-acid glycoprotein and albumin.
Dextromethorphan: ~60-70% (albumin); quinidine: 80-90% (albumin, alpha-1-acid glycoprotein)
1.5-2.5 L/kg (approximates total body water; indicates extensive tissue distribution).
Dextromethorphan: 5-6 L/kg; quinidine: 2-3 L/kg
Oral: 75-95% (immediate-release); IM: 100%; IV: 100%.
Oral: dextromethorphan ~11% (extensive first-pass metabolism; increased to >50% when coadministered with quinidine); quinidine ~70-80%
Cr Cl >50 m L/min: No adjustment. Cr Cl 10-50 m L/min: Administer every 6-12 hours. Cr Cl <10 m L/min: Administer every 12-24 hours.
For creatinine clearance (Cr Cl) 30–59 m L/min: reduce dose to one capsule once daily. For Cr Cl <30 m L/min: not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50%. Child-Pugh Class C: Reduce dose by 50-75% or avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: not recommended (quinidine is extensively metabolized by the liver).
IV: Loading dose: 15 mg/kg over 30-60 minutes, followed by maintenance infusion of 20-80 mcg/kg/min; maximum 2 g/day. Oral: 15-50 mg/kg/day in divided doses every 3-6 hours; maximum 4 g/day.
Safety and efficacy in pediatric patients have not been established; not recommended for use in children.
Start at lower end of dosing range due to age-related decreased renal function and increased risk of hypotension and arrhythmias. Monitor renal function and adjust accordingly.
Initiate at one capsule once daily; titrate cautiously. Monitor for QT prolongation and anticholinergic effects. Lower doses may be required due to age-related renal and hepatic decline.
Procanamide can cause agranulocytosis, leukopenia, and thrombocytopenia; fatal blood dyscrasias have occurred. Frequent blood counts are recommended.
None.
May cause lupus erythematosus-like syndrome (especially with slow acetylator phenotype); proarrhythmic effects (torsades de pointes); hypotension; bone marrow suppression; hepatotoxicity; potentiation of neuromuscular blocking agents.
CNS depression: may cause dizziness, somnolence; avoid alcohol.,Cardiotoxicity: quinidine may cause QT prolongation; monitor ECG.,Serotonin syndrome: risk with concurrent serotonergic drugs.,Hepatic impairment: use with caution.,Renal impairment: not recommended in severe renal disease.
Complete heart block; second- or third-degree AV block without pacemaker; long QT syndrome; torsades de pointes; known hypersensitivity to procainamide or any component.
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days.,Concomitant use with other drugs that prolong QT interval.,Known hypersensitivity to dextromethorphan or quinidine.,Complete atrioventricular block without pacemaker.,History of drug-induced torsades de pointes.
No significant food interactions reported. However, changes in dietary salt intake may affect blood pressure control; avoid excessive caffeine or alcohol as they may trigger arrhythmias. Maintain consistent potassium and magnesium intake; severe electrolyte disbalances can alter drug effect.
Avoid grapefruit and grapefruit juice as they may increase plasma levels of quinidine, raising risk of toxicity including QT prolongation. Avoid excessive alcohol consumption as it may exacerbate CNS depression.
FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use only if clearly needed. In second and third trimesters, chronic use may be associated with fetal bradycardia, QT prolongation, and neonatal lupus syndrome (transient). Avoid in pregnancy if possible.
First trimester: Limited human data; animal studies show quinidine sulfate associated with increased risk of fetal malformations at high doses. Second/third trimester: Dextromethorphan hydrobromide not associated with major malformations; quinidine sulfate may cause fetal bradycardia and hypoglycemia due to quinidine's antiarrhythmic effects. Overall: No adequate human studies; use only if benefit outweighs risk.
Procainamide and its active metabolite NAPA are excreted into breast milk. Milk-to-plasma ratio is approximately 0.8-1.3. Concentrations in milk can reach therapeutic levels. Potential for adverse effects in nursing infant, including bradycardia and hypotension. Use with caution, monitor infant. AAP recommends avoiding use if possible.
Dextromethorphan: Likely excreted in breast milk in low amounts; M/P ratio not reported. Quinidine: Excreted in breast milk; M/P ratio approximately 0.71. Potential for infant quinidine toxicity (cinchonism, arrhythmias). Avoid breastfeeding during maternal quinidine therapy.
Pregnancy alters pharmacokinetics: increased volume of distribution may require higher loading doses (25-30% increase). Decreased plasma albumin reduces protein binding, increasing free fraction. Enhanced renal clearance (due to increased GFR) may necessitate more frequent dosing or dose adjustments. Monitor serum concentrations closely. Start with oral doses of 50 mg/kg/day in divided doses, titrate to effect. Intravenous: initial 100 mg every 5 minutes until arrhythmia controlled, then maintenance 2-6 mg/min with adjustments.
No specific pharmacokinetic studies in pregnancy; increased renal clearance of dextromethorphan in third trimester may lower exposure. For quinidine, plasma protein binding decreases in pregnancy, potentially increasing free drug fraction. Dose adjustment not recommended due to lack of data; titrate based on clinical response and toxicity monitoring.
Procainamide HCL is a Class IA antiarrhythmic used for atrial and ventricular arrhythmias. It can cause lupus-like syndrome, especially in slow acetylators; monitor ANA titers. Renal dose adjustment is critical due to active metabolite N-acetylprocainamide (NAPA) accumulation. Watch for QT prolongation and torsades de pointes; avoid with other QT-prolonging drugs. Administer IV slowly to avoid hypotension; oral loading requires hepatic first-pass consideration.
Monitor for QT prolongation with baseline and periodic ECG, especially in patients with hypokalemia, hypomagnesemia, or bradycardia. Avoid use with CYP3A4 inhibitors (e.g., ketoconazole) or CYP2D6 inhibitors (e.g., paroxetine) due to quinidine metabolism. Quinidine is a potent CYP2D6 inhibitor; caution with concurrent CYP2D6 substrates like tricyclic antidepressants. Onset of pseudobulbar affect improvement may take weeks; titrate dose gradually.
Take this medication exactly as prescribed; do not double doses if missed.,Report any symptoms of lupus (joint pain, rash, fever, chest pain) immediately.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Tell your doctor all other medications, especially other heart rhythm drugs.,You may need regular blood tests to monitor drug levels and organ function.,Do not stop taking this medicine abruptly; sudden stop may worsen arrhythmia.,If using extended-release tablets, do not crush or chew them.
Take this medication exactly as prescribed; do not double doses if missed.,Avoid grapefruit juice as it may increase side effects.,Report any signs of irregular heartbeat (palpitations, dizziness, fainting) or allergic reactions (rash, difficulty breathing).,May cause dizziness or blurred vision; avoid driving until you know how it affects you.,Do not stop abruptly; dose reduction should be gradual under medical supervision.,Inform all healthcare providers about this medication, especially before any surgery or dental procedure.
"Procainamide is a class IA antiarrhythmic that is primarily metabolized by N-acetyltransferase (NAT) and also undergoes CYP2D6-mediated metabolism. Midostaurin, a multikinase inhibitor used for FLT3-mutated AML, is metabolized mainly by CYP3A4. Procainamide can inhibit CYP3A4, reducing the clearance and increasing plasma concentrations of midostaurin, potentially leading to enhanced toxicity including QT prolongation, hepatotoxicity, and myelosuppression."
"Procainamide, a Class Ia antiarrhythmic, prolongs the QT interval by blocking cardiac sodium channels and delaying repolarization. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been associated with QT prolongation, possibly via inhibition of cardiac hERG potassium channels. Concomitant use increases the risk of excessive QT prolongation, potentially leading to torsade de pointes and other ventricular arrhythmias."
"Procainamide, a class Ia antiarrhythmic agent, prolongs the QT interval by blocking cardiac sodium and potassium channels. Pentamidine, used for Pneumocystis pneumonia, also prolongs the QT interval through inhibition of the rapid delayed rectifier potassium current (IKr). Concomitant use can cause additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with electrolyte disturbances or renal impairment."
"The coadministration of nisoldipine, a calcium channel blocker, with quinidine, a Class Ia antiarrhythmic, results in a significant reduction in quinidine serum concentrations. This interaction is primarily due to nisoldipine-induced enhancement of hepatic quinidine metabolism via cytochrome P450 3A4 induction, leading to subtherapeutic quinidine levels and potential loss of antiarrhythmic efficacy. Clinically, patients may experience breakthrough arrhythmias or inadequate suppression of atrial or ventricular arrhythmias."
"Scopolamine, an anticholinergic agent, and Quinidine, a Vaughan-Williams Class Ia antiarrhythmic with anticholinergic properties, exhibit additive anticholinergic effects when coadministered. This synergy can lead to enhanced peripheral and central anticholinergic adverse effects, including dry mouth, blurred vision, urinary retention, constipation, tachycardia, confusion, and cognitive impairment, particularly in elderly patients. The risk is significant as both drugs block muscarinic acetylcholine receptors, potentially precipitating anticholinergic toxicity."
"Vernakalant, a multi-ion channel blocker primarily used for atrial fibrillation conversion, can inhibit cytochrome P450 (CYP) 3A4, the major enzyme responsible for the metabolism of quinidine. This results in elevated plasma concentrations of quinidine, increasing the risk of quinidine-related cardiotoxicity, including QTc prolongation, torsade de pointes, and other ventricular arrhythmias. The interaction may also potentiate vagolytic effects and negative inotropy, leading to hemodynamic compromise."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCAINAMIDE HCL vs DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, answered by our medical review team.
PROCAINAMIDE HCL is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.. DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is a Antiarrhythmic (Class Ia) that works by Dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; quinidine is a CYP2D6 inhibitor that increases dextromethorphan bioavailability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCAINAMIDE HCL and DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCAINAMIDE HCL is: For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.. The standard adult dose of DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is: One capsule (dextromethorphan 20 mg/quinidine 10 mg) orally once daily, with a maximum dose of two capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCAINAMIDE HCL and DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCAINAMIDE HCL is classified as Category A/B. FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use onl. DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is classified as Category A/B. First trimester: Limited human data; animal studies show quinidine sulfate associated with increased risk of fetal malformations at high doses. Second/third trimester: Dextromethor. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.